Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower time to death due to any cause (absolute effect size estimates based… compared with ADT only (moderate certainty).
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher grade III to V adverse events compared with ADT only (low certainty).
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower prostate cancer‐specific death5 compared with ADT only (moderate certainty).
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower time to progression (absolute effect size estimates based on… compared with ADT only (moderate certainty).
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher discontinuation due to adverse events compared with ADT only (low certainty).
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher all adverse events compared with ADT only (low certainty).
Pembrolizumab probably leads to lower time to death from any cause (here: overall mortality at 12‐month compared with chemotherapy (moderate certainty).
Pembrolizumab may leads to higher quality of life (Change from baseline to week 15) compared with chemotherapy (low certainty).
Pembrolizumab probably leads to higher response rate (partial and complete response) compared with chemotherapy (moderate certainty).
Pembrolizumab showed no clear difference in treatment‐related mortality compared with chemotherapy (low certainty).
Pembrolizumab showed no clear difference in discontinuation due to adverse event compared with chemotherapy (low certainty).
Pembrolizumab may leads to lower serious adverse events (irrespective of attribution to treatment) compared with chemotherapy (low certainty).
Bisphosphonates showed no clear difference in proportion of participants with pain response compared with placebo/no treatment (low certainty).
Bisphosphonates probably leads to lower skeletal‐related events: any, composite outcome compared with placebo/no treatment (moderate certainty).
Bisphosphonates showed no clear difference in mortality compared with placebo/no treatment (moderate certainty).
The review found no eligible studies for this question.
Bisphosphonates showed no clear difference in adverse events: nausea compared with placebo/no treatment (moderate certainty).
Bisphosphonates probably leads to higher adverse events: renal compared with placebo/no treatment (moderate certainty).